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Within 6 years, HIV-positive South
African mothers may be able to
confidently and safely breastfeed their
HIV-negative infants to natural weaning
without transmitting the virus, thus
significantly reducing the overall risks of
infant mortality.
That is the goal of an ambitious and
groundbreaking NIH-funded research
project initiated by Professor Jerry
Coovadia, Victor Diatz Professor of
HIV/AIDS Research at the University of
KwaZulu-Natal’s Nelson Mandela
Medical School.
Based on the likelihood of developing
a single prophylactic injection to the
infant every 2 - 3 weeks, the new
methodology promises to boost the
already impressive drop in HIV-positive
infant prevalence brought about by the
current expanding roll-out of
antiretroviral PMTCT drugs.
Tackling HIV breastfeeding
transmission head-on instead of
becoming mired in the often emotive and
contentious ‘Third-World-formula-
feeding’ debate, Coovadia and his
associates at Harvard and in Austria are
convinced they are on the most
scientifically valid track.
‘We all lived through the period when
formula feeding was quite a disastrous
practice and indeed, even now still is.
Breastfeeding simply tops the list of
interventions available for preventing
some of those 11 million deaths of
children under 5 globally each year,’ said
Coovadia.
One of the most underrated social
dangers of the AIDS pandemic in
developing countries is that the risk
currently inherent in breastfeeding may
cause it to go ‘out of fashion’, even
among HIV-negative mothers. This
would inevitably result in a dramatic
increase in the two major infant killers,
diarrhoea and pneumonia.
Coovadia cites research showing that
breastfeeding can reduce all-cause
mortality of children under 5 years old
by 13% in high HIV-prevalence areas and
by 15% in low HIV-prevalence areas.
‘Breastfeeding is still the best option –
almost all the modelling exercises I’ve
seen come to the same conclusion,’ he
says.
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From questionnaires sent out, her
province had identified 1 300 health
care workers who potentially need
dispensing licences but this number was
being ‘carefully scrutinised’, she added.
Both Van Zeil and Putter refuted
claims made by some private sector
doctors that the national health
department requirements for the
licensing examination would disrupt
State health care delivery. Distance
learning and on-the-job learning were
possible and the 300 hours could be
fitted in over 2 - 6  months, the pair
said.
Asked about private providers
contracted to the State, Van Zeil said it
was a ‘somewhat grey area with some
uncertainty’.
‘It appears that those working from a
private facility will not only need a
dispensing license but a permit as well,’
she said.
The law would most affect State
family planning clinics and non-
governmental organisations working
with provinces.
Thompson was awaiting legal
opinion from the national health
department around what was required
for private practitioners, community-
based organisations and private family
planning clinics that rendered services
on the province’s behalf.
‘If we can designate them as
providers then it’s 1 July next year, but
if not then they have to comply
immediately,’ she said. 
Asked how she saw private
practitioners responding to the new
dispensing laws, Putter said much
would depend on the outcome of the
legal challenge to what dispensers saw
as economically unsustainable new
maximum dispensing fees.
‘If the pricing regulations stand, then
I think it may well not be so attractive
to dispense anymore,’ she said.
Putter said the new laws meant that
the English maxim of ‘the King can do
no wrong’, that the State had applied to
itself in this area of health care, would
be buried forever from 1 July 2005.
Thompson said the Western Cape was
‘trying to model this for other provinces
– national will try and help them to
replicate what is being done here’.
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colleagues of his had established the
precise levels of infant mortality below
which it was safe to formula feed and
above which it was dangerous to
formula feed. Infant mortality remained
one of the best-known markers for socio-
economic conditions.
Coovadia said his idea of using a
prophylactic injection was born of
reading the work of Professor Ruth
Ruprecht at the Dana-Farber Cancer
Institute of Harvard University more
than 2 years ago.
Ruprecht created a model of neonatal
Simian immune virus (SIV) transmission
and used monoclonal antibodies to
prevent transmission. Using an SIV
coated with human envelope proteins,
she created a surrogate response to the
human virus – with remarkable success.
Coovadia immediately saw the
potential for reducing mother-to-child
breastfeeding transmission and, with
Ruprecht’s collaboration, began writing
up a proposal for an NIH grant. The
NIH was initially concerned about the
likelihood of antibodies being produced
but was eventually convinced that the
idea had serious potential.
Together with his local colleague,
Deseree Archary, a private Austrian
company that manufactures human
monoclonal antibodies, and experts in
pharmacotherapeutics and other related
fields, Coovadia’s international team is
about to embark on phase 1 of their
trials.
‘We have just over R1 million to find
out the safety and tolerance levels and
ascertain the dose in a sample of 30 - 40
HIV-negative infants born of HIV-
positive mothers,’ he revealed. Once this
has been established, a much larger
sample (many hundreds) of HIV-
negative infants born of HIV-positive
mothers will be injected (phase 3 trials).
‘We’ll have to plan very carefully – it’s
quite a dilemma because what would be
our control group?’ Coovadia said,
adding that the best-proven treatment
for a developing country would have to
be used. He said a United States research
group had wanted to use Ruprecht’s
work to treat HIV-infected babies but
had not got their project off the ground.
‘We’re hoping that in the longer term it
will have a role to play in HIV vaccines.
It’s a bit like a hepatitis B vaccine, where
you give both an active vaccine and
combine it with a passive antibody.’
Coovadia said ‘huge advances’ have
been made in the prevention of HIV
transmission from mother to child with
figures down from highs of between 30%
and 35% to just 1% or 2%.
‘But the one thing we do not have a
good answer to is breastfeeding. The big
unanswered question is breastfeeding
transmission.  We know that if you avoid
it altogether you come to a zero sum
transmission, but formula feeding is not
the answer in Third-World countries. We
have to find an alternative, and at
present there is not one.’
He explained that even if the current
nevirapine prophylaxis trials for
breastfeeding transmission proved
successful, the ‘hassle’ of infants taking
nevirapine daily, plus resistance and
side-effects, made a far less frequent 
single injection a very attractive option.
Study paediatricians would be the first
line of defense against any potential
problems, followed by a local safety
review, the NIH Statistics and Safety
Division, and then the Data Safety
Monitoring Committee. Safety trials had
already been successfully concluded in
adults, using a combination of three
antibodies.
Coovadia’s team expected to receive
the final NIH go-ahead by the end of
July, followed by the local ethics
committee executive decision a fortnight
later. The biggest delay could be the
Medicines Control Council – that could
take 3 months or longer, he said. Asked
how long it would take for the injection
to be finally proved effective and made
available to the public, Coovadia replied,
‘Five to six years, if all goes well’.
Two years ago there were an estimated
80 000 South African infants being
infected annually with the HIV virus and
modellers believe that a reasonable
current annual estimate (given the
PMTCT programme) is about half this.
Being able to eliminate breastfeeding
transmission will help transform the
paradigm even further.
Chris Bateman
